Washington: A new study by the US Centers for Disease Control and Prevention (CDC) shows that the efficacy of a third dose of Pfizer and Moderna’s mRNA vaccine is significantly reduced by 4 months after administration. The decline in vaccine efficacy after two doses is now well documented, but relatively little is known about the duration of protection after booster immunization.
The new study found more than 241,204 visits to emergency departments or clinics and more serious 93,408 hospitalizations in adults with COVID-19-like illness from August 26, 2021 to January 22, 2022. Was based on. Vaccine efficacy compares the probability of positive COVID testing in vaccinated and unvaccinated patients and uses statistical techniques to patients with age, level of local infection, and comorbidities. Estimated by controlling the geographical area during the calendar week, adjusting the characteristics of.
During the period of Omicron’s predominance, vaccine efficacy for COVID-related emergency or emergency treatment visits decreased from 87% in the two months after the third dose to 66% by the fourth month. .. The effectiveness of the vaccine for hospitalization was 91% in the first two months, but decreased to 78% by the fourth month after the third dose.
“The finding that RNA vaccine protection weakened months after receiving the third vaccine underscores the importance of further consideration of additional doses to maintain or improve protection.” The authors concluded. At the White House COVID briefing on Wednesday, President Joe Biden’s chief medical adviser, Anthony Fauci, said a fourth dose was needed for a subset of people with weak immune responses, such as the elderly and weakened immunity. Said that it is likely to be.
In another development on Friday, the Food and Drug Administration (FDA) approved a new laboratory-grown antibody treatment by pharmaceutical company Lilly called Bebutellobimab. The drug is given as an intravenous injection for at least 30 seconds and is given a green light for the treatment of mild to moderate COVID in people over the age of 12 who are at high risk for severe illness. The data supporting the approval came from clinical trials showing that the drug has strong expectations for Omicron. Lily’s previous antibody treatment was revoked by the FDA after it was found to be ineffective against this variant.
Meanwhile, the World Health Organization announced on Friday that it had pre-certified tocilizumab for the treatment of arthritis for patients hospitalized with severe COVID-19 to increase access to expensive medicines. Monoclonal antibodies used in anti-inflammatory drugs manufactured by Swiss pharmaceutical giant Roche have been shown to reduce the risk of death and length of hospital stay in certain patients suffering from severe COVID.
WHO has already recommended its use in the treatment of severe COVID in hospitals, as in the United States and the European Union. But it’s still scarce and very expensive. In low-income countries, a single dose is reported to be up to $ 600. The United Nations Health Agency said it has added three different compositions of monoclonal antibodies to the list of pre-certified treatments for pandemic diseases with the aim of promoting the production of cheaper generic versions.
WHO told AFP that the pre-certification process is primarily aimed at ensuring the quality, safety and effectiveness of medical products procured in developing countries. Pre-qualification ensures that each country purchases high quality health products. Prior to tocilizumab, WHO pre-certified three different compositions of the steroid dexamethasone and Gilead’s antiviral remdecibir for the treatment of COVID, but the pre-certification was subsequently discontinued.
Tocilizumab has been approved primarily for the treatment of arthritis in approximately 120 countries. However, during a pandemic, it has also been shown to suppress a dangerous “cytokine storm,” an overreaction of the immune system to coronavirus. WHO pointed out that the tocilizumab patent has expired for most uses. This warned that “the global availability of biosimilars with guaranteed product quality is low,” but “means that there should be no intellectual property barriers.”
WHO officials also said Friday that the acute phase of the pandemic could end this year if about 70% of the world is vaccinated. Tedros Adhanom Gebreyes told South African reporters, “We expect the acute phase of this pandemic to end this year. Of course, under one condition, 70% vaccination by the middle of this year (target). Will be achieved) will be around June and July. ” “If that happens, the acute phase can really end and that’s what we expect. It’s in our hands. It’s not a matter of chance. It’s a matter of choice. is.”
He was speaking during his visit to Afrigen Biologics and Vaccines. It produced the first mRNA COVID vaccine made in Africa using the Moderna sequence. “We expect this vaccine to be less storage-constrained, cheaper, and more suitable for the situation in which it is used,” said the WHO boss. The vaccine is ready for clinical trials in November and is expected to be approved in 2024.
Afrigen is leading a pilot project, supported by the WHO and COVAX initiatives. Founded in July, the Technology Transfer Hub trains other countries and distributes production licenses to poor countries left behind in the race for life-saving shots. “We are committed to supporting the development of local manufacturing in Africa and around the world to increase the safety of local health,” Tedros said.
Over 11% of Africans are vaccinated, the lowest rate in the world. Last week, WHO’s Africa office said the continent must increase vaccination rates “six times” to reach the 70% target. South Africa and India have been calling for a vaccine patent or intellectual property exemption for the COVID-19 vaccine since October 2020, saying it will help promote local production.
However, many wealthy nations hosting major pharmaceutical companies are opposed to this move and believe it will discourage innovation. However, the World Trade Organization announced last month that an agreement between wealthy and developing countries on IP exemption could be just a few weeks away. -agency
https://www.kuwaittimes.com/booster-efficacy-wanes-significantly-by-fourth-month/ Booster effect will be significantly reduced by the 4th month